Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 10:01 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2209–2232 of 33,158 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: PLACEBO Clear all

Conditions: Asthma
Interventions: MN-221, Placebo; Drug
Lead sponsor: MediciNova; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 4
States / cities: Lenexa, Kansas • North Dartmouth, Massachusetts • Rolla, Missouri + 1 more

Conditions: Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction
Interventions: JK07, Placebo; Drug
Lead sponsor: Salubris Biotherapeutics Inc; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 51
States / cities: Alexander City, Alabama • Birmingham, Alabama • Huntsville, Alabama + 45 more

Conditions: Alcoholism
Interventions: mecamylamine, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2015
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Long COVID, Long Coronavirus Disease 2019 (Covid19), Long Covid-19
Interventions: IVIG (intravenous immunoglobulin), IVIG Placebo, Coordinated Care, Usual Care; Drug · Behavioral
Lead sponsor: Kanecia Obie Zimmerman; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Interstitial Lung Disease
Interventions: efzofitimod 450 mg, efzofitimod 270 mg, Placebo; Drug
Lead sponsor: aTyr Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 15
States / cities: Los Angeles, California • San Diego, California • Miami, Florida + 10 more

Conditions: Bipolar I Disorder, Depression, Anxiety, Stress
Interventions: Magnesium vitamin B6, Placebo; Drug
Lead sponsor: Mclean Hospital; Other
Eligibility: 18 Years to 50 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Belmont, Massachusetts

Conditions: Parkinson's Disease
Interventions: MEDI1341, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 5
States / cities: Long Beach, California • Hallandale, Florida • Atlanta, Georgia + 2 more

Conditions: Stroke, Muscle Spasticity, Hemiparesis
Interventions: Cyproheptadine, Placebo for Cyproheptadine, Active Movement Practice (AMP), Passive Cyclical Stretching; Drug · Other
Lead sponsor: Shirley Ryan AbilityLab; Other
Eligibility: 18 Years to 80 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Overweight, Obesity
Interventions: NNC0662-0419, Placebo (NNC0662-0419); Drug · Other
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Healthy
Interventions: TT-00920, TT-00920 Placebo; Drug
Lead sponsor: TransThera Sciences (Nanjing), Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Classic Galactosemia
Interventions: AT-007, Placebo; Drug
Lead sponsor: Applied Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 114 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 4
States / cities: Anaheim, California • Atlanta, Georgia • Boston, Massachusetts + 1 more

Conditions: Interdigital Tinea Pedis
Interventions: Econazole Nitrate, placebo; Drug
Lead sponsor: AmDerma; Industry
Eligibility: 12 Years to 18 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: San Diego, California

Conditions: Immune Response, Inflammation
Interventions: Blueberry powder group, Placebo powder group; Dietary Supplement
Lead sponsor: Loma Linda University; Other
Eligibility: 50 Years to 70 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Healthy
Interventions: Clopidogrel, Placebo, Omeprazole; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Psoriasis
Interventions: MEDI-507; Drug
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001
U.S. locations: 3
States / cities: Phoenix, Arizona • Winston-Salem, North Carolina • Tacoma, Washington

Conditions: Cluster Headache
Interventions: Fremanezumab; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 32
States / cities: Phoenix, Arizona • Canoga Park, California • Santa Monica, California + 27 more

Conditions: Schizophrenia
Interventions: N-acetylcysteine (NAC), Inactive placebo capsule; Drug
Lead sponsor: VA Greater Los Angeles Healthcare System; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Ovarian Neoplasms, Ascites
Interventions: aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®), Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Benralizumab, Placebo; Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 689 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 84
States / cities: Surprise, Arizona • Little Rock, Arkansas • Los Angeles, California + 77 more

Conditions: Submental Fat
Interventions: RZL-012, Placebo; Drug
Lead sponsor: Raziel Therapeutics Ltd.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 151 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Gastroesophageal Reflux
Interventions: Dexlansoprazole, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 305 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 43
States / cities: Tucson, Arizona • Anaheim, California • Garden Grove, California + 40 more

Conditions: Dysphonia
Interventions: Lansoprazole, Placebo; Drug · Other
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 3 Years to 18 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Hormone-Resistant Prostate Cancer, Prostate Adenocarcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
Interventions: Laboratory Biomarker Analysis, Placebo, Tivantinib; Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 20
States / cities: Washington D.C., District of Columbia • Tampa, Florida • Chicago, Illinois + 14 more

Conditions: Benign Prostatic Hyperplasia
Interventions: WC3055, Placebo; Drug · Other
Lead sponsor: Warner Chilcott; Industry
Eligibility: 45 Years and older · Male only
Enrollment: 796 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 95
States / cities: Homewood, Alabama • Huntsville, Alabama • Mobile, Alabama + 80 more

Search by objective public record fields.

Study Evaluating the Safety and Effects of MN-221 in Subjects With Moderate to Severe Asthma

Study of JK07 in Patients With Chronic Heart Failure

Treatment With Mecamylamine in Smoking and Non-smoking Alcohol Dependent Patients

RECOVER-AUTONOMIC: Platform Protocol, Appendix A (IVIG)

Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)

Efficacy and Safety of Magnesium Vitamin B6 in First Episode Bipolar Disorder

Multiple Ascending Dose Study of MEDI1341 in Patients With Parkinson's Disease

Altering Activation Patterns Post-stroke

A First-in-human Research Study on How NNC0662-0419 Works in People Living With Overweight or Obesity

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Dose of TT-00920 in Healthy Subjects

Safety and Pharmacokinetics of AT-007 in Healthy Subjects and in Adult Subjects With Classic Galactosemia

Comparative PK Study of Econazole Nitrate Foam and Econazole Nitrate Cream in Subjects With Interdigital Tinea Pedis Aged 12 Years to Less Than 18 Years

Effect of Blueberries on Immunity

Interaction Study of Clopidogrel 600/150 mg Given Alone or Concomitantly With Omeprazole 80 mg in Healthy Subjects

Study of MEDI-507 Administered by Intravenous Infusion to Adults With Plaque Psoriasis

A Study to Explore the Long-Term Safety and Efficacy of Fremanezumab (TEV-48125) for the Prevention of Cluster Headache

N-acetylcysteine (NAC) for Improving Cognitive Dysfunction in Schizophrenia

Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites

Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations

Efficacy and Safety of RZL-012 on Submental Fat Reduction

A Study of Dexlansoprazole Modified Release Formulation to Treat Night Heartburn

Dietary Control Alone Versus Dietary Control Plus Use of Proton Pump Inhibitors to Treat Pediatric Hoarseness

Tivantinib in Treating Patients With Metastatic Prostate Cancer

Assess Safety & Efficacy of WC3055 in Men With Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia